Securing the Future: Shaping the UK Strategy of Long-acting Therapeutics

The UKRI-funded Hub for Advanced Long-acting Therapeutics (HALo) brought together leading experts from industry, healthcare, and government for a national strategy meeting to discuss how the UK can strengthen its leadership in long-acting therapeutics.

The event, Securing the Future: Shaping the UK Strategy of Long-acting Therapeutics, was jointly hosted by HALo, the Infection Innovation Consortium (iiCON), CPI, and the Henry Royce Institute.

Long-acting therapeutics – pharmaceutical agents and drug-delivery systems that release medication slowly and consistently over extended periods – represent a transformative area of medicine with the potential to significantly improve treatment adherence and patient outcomes.

A national facility, HALo aims to position the UK as a global leader in this emerging field and is part of Centre of Excellence for Long-acting Therapeutics Global Health (CELT Global Health).

It is led by the University of Liverpool and partners include the University of Manchester and CPI.

For more information read here.